

1515 North Saint Joseph Avenue PO Box 8000 Marshfield, WI 54449-8000

1.800.472.2363 | 715.221.9555 TTY: 711

Hyaluronic Acid Derivatives

Prior Authorization Re	quest	Date		
Member information		LCMID	Data of hinth ()	()
Member name (print)		SMID	Date of birth (month/day.	/year)
Provider information				
Provider name (print)		Telephone number	Fax number	
Place of service: Ambulatory Surg	Other		•	
Facility where services will be provided (in	clude address if the provider provide	es services at more than one pra	ictice location)	
Contact person name (print)		Telephone number	Fax number	
Procedure information				
Scheduled date of service (month/day/year)	Requested service/procedure		Procedure code(s)	
Diagnosis	<u> </u>	Diagnosis code(s)		
medications: Hyalgan and Gel-One Is the hyaluronic acid derivatives fo				
-				_
– Euflexxa				_ N∙
– Durolane				_ N∙
– GelSyn				_ N∙
– GenVisc			······································	_ N∙
– Hymovis				_ N
– Monovisc			<u> </u>	_ N
– Orthovisc				N
– Supartz				\square N
– Supartz FX				\square N
– Synvisc				\square N
– Synvisc-One				\square N
– Trivisc		Yes	\square N	
– Visco-3			Yes	\square N
If not on the list, what medicati	on			

	or osteoarthritis of the knee: documented symptomatic osteoart	hritis of the knee Yes	□No
•	inadequate response, contraindicati l-one and Hyalgan)	on or intolerance to the Yes	□No
pharmacotherapy [e.g., (up to 1 g 4 times/day)	ial and failure of conservative therap non-steroidal anti-inflammatory dru and/or topical capsaicin cream]) has mprovement after at least 3 months	ugs (NSAIDs), acetaminophen	□No
Has the member failed t	to adequately respond to aspiration a	and injection of intra-articular steroids \square Yes	□No
·	ed pain which interferes with functi	onal activities (e.g., ambulation,	□No
There are no contraindi	cations to the injections (e.g., active	gioint infection, bleeding disorder) \square Yes	□No
If contraindications	, please document		
Is this continued infusion	on for osteoarthritis of the knee:		
analgesics or anti-	edical record demonstrates a reducti -inflammatory medication) during th finjections.		□No
	edical record objectively documents pacity as the result of the previous in	significant improvement in pain njections Yes	□No
Examples of unac	sence of unacceptable toxicity from ceptable toxicity include: severe join ylactic or anaphylactoid reactions, e	•	□No
		formation is accurate and documented in the me medical records to make a final coverage detern	
Provider signature			
calendar days of re		erage determination is made within fourteen (14 or provider are notified in writing of a denial de quest.	
	cisions: Initial review is received and ours of receipt of request.	d a coverage determination is made within	
Mail or fax form to:	Security Health Plan Health Services Department PO Box 8000 Marshfield, WI 54449-8000	Marshfield Clinic providers route to: Health Services Department Routing location, SHP	
	Fax 715-221-6616		

If you have any questions, please contact Customer Service at 1-800-548-1224